Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib versus teriflunomide in relapsing multiple sclerosis with open-label remibrutinib extension
MOH_2023-07-19_012832Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib and teriflunomide in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) (3 arms), sponsored by Novartis. Started Jul 2023; status: active, not recruiting.
02
Drugs
remibrutinibteriflunomide
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on MOH_2023-07-19_012832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-19_012832.